FGF23 is associated with early post-Transplant hypophosphataemia and normalizes faster than iPTH in living donor renal transplant recipients: A longitudinal follow-up study

Clinical Kidney Journal

Volumn 9, Issue 5, 2016, Pages 669-676

  Prasad, Narayan ^a   Jaiswal, Akhilesh ^a   Agarwal, Vikas ^a   Kumar, Shashi ^a   Chaturvedi, Saurabh ^a   Yadav, Subhash ^a   Gupta, Amit ^a   Sharma, Raj K ^a   Bhadauria, Dharmendra ^a   Kaul, Anupama ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Fibroblast growth factor 23; Hyperparathyroidism; Hypophosphataemia; Intact parathyroid hormone; Renal transplantation

Indexed keywords

CREATININE; CYCLOSPORIN; FIBROBLAST GROWTH FACTOR 23; MYCOPHENOLATE MOFETIL; PARATHYROID HORMONE; PREDNISOLONE; TACROLIMUS; UREA; URIC ACID;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LIVING DONOR; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 84995553797     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfw065     Document Type: Article

References (46)

1. Justin S, Tally NM. FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol 2013; 9: 641-649.
2. Gutiérrez OM, Mannstadt M, Isakova Tet al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
3. Jean G, Terrat JC, Vanel T et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2792-2796.
4. Kendrick J, Cheung AK, Kaufman JS et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913-1922.
5. Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010; 61: 91-104.
6. Stubbs J, Liu S, Quarles D. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007; 20: 302-308.
7. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor- 23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215.
8. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608.
9. Marsell R, Grundberg E, Krajisnik T et al. Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. Eur J Endocrinol 2008; 158: 125-129.
10. Xoana B, Jose-Vicente T. Role of FGF23 in kidney transplantation. J Transplant Technol Res 2011; S1: 002.
11. Green J, Debby H, Lederer E et al. Evidence for a PTH independent humoral mechanism in post-Transplant hypophosphatemia and phosphaturia. Kidney Int 2001; 60: 1182-1196.
12. Parfitt AM, Kleerekoper M, Cruz C. Reduced phosphate reabsorption unrelated to parathyroid hormone after renal transplantation: implications for the pathogenesis of hyperparathyroidism in chronic renal failure. Miner Electrolyte Metab 1986; 12: 356-362.
13. Rosenbaum RW, Hruska KA, Korkor A et al. Decreased phosphate reabsorption after renal transplantation: evidence for a mechanism independent of calcium and parathyroid hormone. Kidney Int 1981; 19: 568-578.
14. Bhan I, Shah A, Holmes J et al. Posttransplant hypophosphatemia: Tertiary hyper-phosphatoninism? Kidney Int 2006; 70: 1486-1494.
15. Pande S, Ritter CS, Rothstein M et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006; 104: 23-32.
16. Evenepoel P, Naesens M, Claes K et al. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007; 7: 1193-1200.
17. Miyamoto KI, Ito M, Kuwahata M et al. Inhibition of intestinal sodium dependent inorganic phosphate transport by fibroblast growth factor 23. Ther Apher Dial 2005; 9: 331-335.
18. Trombetti A, Richert L, Hadaya K et al. Early post-Transplantation hypophosphatemia is associated with elevated FGF-23 levels. Eur J Endocrinol 2011; 164: 839-847.
19. Evenepoel P, Meijers BK, de Jonge, H et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008; 3: 1829-1836.
20. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl 3): S1-S201.
21. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87: 4957-4960.
22. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
23. Economidou D, Dovas S, Papagianni A et al. FGF-23 levels before and after renal transplantation. J Transplant 2009; 2009: 379-382.
24. Lobo PI, Cortez MS, Stevenson W et al. Normocalcemic hyperparathyroidism associated with relatively low 1:25 vitamin D levels post-renal transplant can be successfully treated with oral calcitriol. Clin Transplant 1995; 9: 277-281.
25. Parfitt A. Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 1982; 8: 92-112.
26. Evenepoel P, Meijers B, Viaene L et al. Fibroblast growth factor- 23 in early chronic kidney disease: Additional support in favor of aphosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5: 1268-1276.
27. Mirams M, Robinson BG, Mason RS et al. Bone as a source of FGF23: regulation by phosphate? Bone 2004; 35: 1192-1199.
28. Krocker D, Perka C, Tuischer J et al. Effects of tacrolimus, cyclosporin A and sirolimus on MG63 cells. Transpl Int 2006; 19: 563-569.
29. Kawarazaki H, Shibagaki Y, Fukumoto S et al. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: A 1-year prospective observational study. Nephrol Dial Transplant 2011; 26: 2691-2695.
30. Evenepoel P, Claes K, Kuypers D et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study. Nephrol Dial Transplant 2004; 19: 1281-1287.
31. Levi M. Post-Transplant hypophosphatemia. Kidney Int 2001; 59: 2377-2387.
32. Ramezani M, Einollahi B, Asl MA et al. Calcium and phosphorus metabolism disturbances after renal transplantation. Transplant Proc 2007; 39: 1033-1035.
33. Kawarazaki H, Shibagaki Y, Shimizu H et al. Persistent high level of fibroblast growth factor 23 as a cause of post-renal transplant hypophosphatemia. Clin Exp Nephrol 2007; 11: 255-257.
34. Farrow EG, Davis SI, Summers L et al. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 2009; 20: 955-960.
35. Isakova T, Gutierrez OM, Wolf M. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int 2009; 76: 705-716.
36. Shigematsu T, Kazama J, Yamamashita T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250-256.
37. Ghanekar H, Welch BJ, Moe OW et al. Post-renal transplantation hypophosphatemia: A review and novel insights. Curr Opin Nephrol Hypertens 2006; 15: 97-104.
38. Wrong O. Nephrocalcinosis. In: Davidsen AM, Cameron JS, Grunfeld JP (eds). Oxford Textbook of Clinical Nephrology. Oxford: Oxford University Press, 1998, 1375-1396.
39. Schankel K, Robinson J, Bloom RD et al. Determinants of coronary artery calcification progression in renal transplant recipients. Am J Transplant 2007; 7: 2158-2164.
40. Mazzaferro S, Pasquali M, Taggi F et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol 2009; 4: 685-690.
41. Kurella M, Butterly DW, Smith SR. Posttransplant erythrocytosis in hypercalcemic renal transplant recipients. Am J Transplant 2003; 3: 873-877.
42. Frick TW, Fryd DS, Sutherland DE et al. Hypercalcemia associated with pancreatitis and hyperamylasemia in renal transplant recipients: data from the Minnesota randomized trial of cyclosporine versus antilymphoblast azathioprine. Am J Surg 1987; 154: 487-489.
43. Brunelli SM, Goldfarb S. Hypophosphatemia: clinical consequences and management. J Am Soc Nephrol 2007; 18: 1999-2003.
44. Liu S, Brown TA, Zhou J et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 2005; 16: 1645-1653.
45. Emmett M. What does serum fibroblast growth factor 23 do in hemodialysis patients? Kidney Int 2008; 73: 3-5.
46. Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with earlystage chronic kidney disease. Kidney Int 2010; 78: 975-980.